Month: July 2023

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO). Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. She most recently served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc. “Jacqui’s breadth of expertise across securities, business development, regulatory, intellectual property, and multiple other legal disciplines makes her a strong addition to the growing Voyager team,” said Al Sandrock, M.D., Ph.D., Chief Executive Officer of Voyager. “In addition to her impressive subject matter expertise,...

Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported outcomes from the initial 16-week treatment period with rademikibart (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis (AD) in the pivotal CN002 trial in ChinaSAN DIEGO and TAICANG, China, July 10, 2023 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced it presented four posters at the 25th World Congress of Dermatology being held...

SAN JOSE, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that KAMO Electric Cooperative, Inc. (KAMO Power) is deploying Infinera’s XTM Series on its 2,700-route-mile rural network to serve its 17 member cooperatives across northeast Oklahoma and southwest Missouri. The deployment upgrades KAMO Power’s network, providing the cooperative with an open optical network that delivers high-capacity, reliable, and secure transport services. KAMO Power is a Generation and Transmission (G&T) cooperative and one of the largest of its kind, providing its members safe, cost-effective, and reliable power through its high-voltage transmission network and communications system. In addition to serving the region as the largest power source, KAMO Power’s cooperative members rely on its robust open optical network...

— Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones— Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The modification provides new development milestones associated with the achievement...

TORONTO, July 10, 2023 (GLOBE NEWSWIRE) — Sulliden Mining Capital Inc. (TSX: SMC) (“Sulliden” or the “Company”) is pleased to announce it has entered into a share purchase and subscription agreement dated July 9, 2023, pursuant to which the Company has agreed to purchase and subscribe for up to 70% of the total issued and authorised ordinary par value shares of a Namibian private company (“Privco”), subject to the terms and conditions set out in the agreement (the “Transaction”). Privco holds, either directly or through option agreements, 14 exclusive prospecting licenses representing 307,778 hectares of exploration licenses, including the Khorixas Gold Project, the Omatjete Gold and Lithium Project, and the Outjo Gold Project (collectively, the “Damara Project”). The Damara Project is anticipated to provide Sulliden access to...

Majuro, Marshall Islands,, July 10, 2023 (GLOBE NEWSWIRE) —  GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) today announced the availability of the Partnership’s 2022 Sustainability Report. The Sustainability Report, which can be accessed on the Partnership’s website, has been compiled in general compliance with the Sustainability Accounting Standards Board (“SASB”) Marine Transportation standard. In the Report, GasLog Partners summarizes progress delivered around the focus areas of decarbonization, safety and wellbeing, and diversity, equity and inclusion, among other areas. GasLog Partners LP 2022 Sustainability Report: www.gaslogmlp.com/investors/sustainability Contacts: Robert Brinberg Rose & Company Phone: +1 212-517-0810 Email: gaslog@roseandco.com About GasLog Partners GasLog Partners is an...

Company to voluntarily delist from the Toronto Stock Exchange (TSX) Last trading day on TSX will be July 21, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, today announced that it intends to consolidate trading of its shares on the Nasdaq exchange and as such has applied and received approval for a voluntary delisting of its common shares from the Toronto Stock Exchange (“TSX”). The last trading day on TSX will be July 21, 2023. The delisting from the TSX will not affect the Company’s listing on the Nasdaq and common shares will continue to trade...

VANCOUVER, Canada, July 10, 2023 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to report oxide mineralized targets identified for resource expansion at the Company’s Cerro Caliche gold project, located in Sonora State, Mexico. Surface sampling and detailed geologic mapping completed in the northwest region of the property demonstrate three linear structural corridor repetitions with anomalous gold, silver and base metal mineralization, as well as a fourth visually inferred corridor. Exploration to date at Cerro Caliche has identified a wide area of mineralized low-sulfidation epithermal vein structures and the presence of multiple northwest trending gold mineralized zones along trend and at near surface. A Mineral Resource Estimate report filed in March 2023 confirmed...

TORONTO, July 10, 2023 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announced preliminary production results from both of its mines and smelter for the three and six months ended June 30, 2023. “Our mining operations continue to perform well and delivered another strong quarter of production in the second quarter,” said David Rae, President and Chief Executive Officer. “Our strong performance year-to-date positions us well to achieve our 2023 guidance targets for gold and copper production.” Production Highlights Preliminary results for the second quarter and six months are provided in the table below:  Ore processed Metals contained in concentrate produced Payable metals in concentrate sold Complex concentrate smelted  (Kt) Gold(K oz.) Copper (Mlbs.) Gold(K oz.) Copper (Mlbs.) (Kt)Q2...

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC). The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions. The Phase I/II study is an open-label, multi-centered, randomized clinical trial designed to evaluate the safety and efficacy of MW005 in patients with BCC. All of the patients enrolled in the study had histologically...